[go: up one dir, main page]

CO2019005729A2 - Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos - Google Patents

Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos

Info

Publication number
CO2019005729A2
CO2019005729A2 CONC2019/0005729A CO2019005729A CO2019005729A2 CO 2019005729 A2 CO2019005729 A2 CO 2019005729A2 CO 2019005729 A CO2019005729 A CO 2019005729A CO 2019005729 A2 CO2019005729 A2 CO 2019005729A2
Authority
CO
Colombia
Prior art keywords
preparation
supply
active pharmaceutical
pharmaceutical ingredients
ophthalmic
Prior art date
Application number
CONC2019/0005729A
Other languages
English (en)
Inventor
Thorsteinn Loftsson
Zoltan Fulop
Original Assignee
Oculis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61656066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019005729(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oculis SA filed Critical Oculis SA
Publication of CO2019005729A2 publication Critical patent/CO2019005729A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

RESUMEN La presente divulgación se relaciona con composiciones oftálmicas que contienen complejos sólidos de ingrediente activo farmacéutico y ciclodextrina, con su método de preparación y sus usos; las composiciones pueden incluir un complejo de fármaco de agente activo / ciclodextrina sustancialmente disuelto en un vehículo acuoso de gotas oftálmicas; la composición oftálmica está generalmente en la forma de una microsuspensión que incluye un complejo de agente activo que tiene un diámetro menor a aproximadamente 100 µm.
CONC2019/0005729A 2016-11-29 2019-05-31 Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos CO2019005729A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427737P 2016-11-29 2016-11-29
PCT/IB2017/001659 WO2018100434A1 (en) 2016-11-29 2017-11-29 Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery

Publications (1)

Publication Number Publication Date
CO2019005729A2 true CO2019005729A2 (es) 2019-08-30

Family

ID=61656066

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0005729A CO2019005729A2 (es) 2016-11-29 2019-05-31 Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos

Country Status (31)

Country Link
US (7) US20190343846A1 (es)
EP (2) EP4194011A1 (es)
JP (2) JP7138103B2 (es)
KR (3) KR102774277B1 (es)
CN (2) CN117018220A (es)
AR (2) AR110269A1 (es)
AU (1) AU2017369971B2 (es)
CA (1) CA3045226A1 (es)
CL (1) CL2019001447A1 (es)
CO (1) CO2019005729A2 (es)
CY (1) CY1124917T1 (es)
DK (1) DK3548091T3 (es)
EA (1) EA201991299A1 (es)
ES (1) ES2903383T3 (es)
HR (1) HRP20220046T1 (es)
HU (1) HUE057221T2 (es)
IL (2) IL310360A (es)
LT (1) LT3548091T (es)
MA (1) MA46997B1 (es)
MD (1) MD3548091T2 (es)
MX (1) MX389363B (es)
PH (1) PH12019550088A1 (es)
PL (1) PL3548091T3 (es)
PT (1) PT3548091T (es)
RS (1) RS62845B1 (es)
SI (1) SI3548091T1 (es)
SM (1) SMT202200025T1 (es)
TW (2) TWI810167B (es)
UA (1) UA124774C2 (es)
WO (1) WO2018100434A1 (es)
ZA (1) ZA201903307B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117018220A (zh) 2016-11-29 2023-11-10 奥库里斯经营管理有限责任公司 用于眼用活性药物成分递送的固体环糊精复合物的制备
IT201900000561A1 (it) * 2019-01-14 2020-07-14 Medivis S R L Formulazioni topiche oftalmiche chimicamente e fisicamente stabili a base di Nepafenac
CN110051859B (zh) * 2019-06-06 2020-06-12 鲁南制药集团股份有限公司 一种阿昔替尼环糊精包合物
US12097209B2 (en) * 2019-07-01 2024-09-24 Oculis Operations Sàrl Diabetic retinopathy treatment with stabilized dexamethasone
TWI756547B (zh) * 2019-07-15 2022-03-01 高雄榮民總醫院 奈米眼藥水及其製造方法
EP4138841B1 (en) * 2020-04-24 2024-10-23 Lan Tech Limited A formulation for treating ophthalmic conditions
TW202216119A (zh) * 2020-06-30 2022-05-01 瑞士商歐庫利斯公司 眼用活性醫藥成分輸送的固態環糊精複合物製備
CN111728953B (zh) * 2020-07-29 2023-08-08 中国科学院上海药物研究所 一种托法替布或其盐的缓释制剂及其制备方法
WO2022158893A2 (ko) * 2021-01-21 2022-07-28 주식회사태준제약 점안 조성물
WO2022156371A1 (zh) * 2021-01-22 2022-07-28 成都瑞沐生物医药科技有限公司 一种眼用制剂的载体或辅料及其制备方法和应用
US11998562B2 (en) * 2021-01-25 2024-06-04 University Of South Florida Ophthalmological formulations for the prevention of a coronavirus infection
WO2023039213A1 (en) * 2021-09-09 2023-03-16 Biora Therapeutics, Inc. Aqueous formulations of tofacitinib and tofacitinib salts
WO2023132947A1 (en) * 2022-01-05 2023-07-13 The Regents Of The University Of California Closo-dodecaiododecaborate complexes and methods of use for same
WO2023148231A1 (en) 2022-02-02 2023-08-10 Oculis SA Multidose ophthalmic compositions
CN118892544A (zh) * 2023-04-28 2024-11-05 维眸生物科技(浙江)有限公司 一种用于治疗非感染性炎症疾病的眼科组合物
TW202508583A (zh) * 2023-08-28 2025-03-01 碩德生技股份有限公司 低溶解度物質的眼用組合物之製備方法
WO2025082585A1 (en) 2023-10-16 2025-04-24 Oculis Operations Sàrl Method of treating diabetic macular edema
WO2025083031A1 (en) 2023-10-16 2025-04-24 Oculis Operations Sàrl Method of treating diabetic macular edema

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
ATE147619T1 (de) 1992-05-13 1997-02-15 Sandoz Ag Opthalmische zusammensetzungen enthaltend ein cyclosporin
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
EP0709099A3 (en) 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
US20020198174A1 (en) * 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
TR200101790T2 (tr) 1998-12-23 2001-10-22 Idea Ag. Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül
DE10036871A1 (de) 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
WO2002039993A2 (en) * 2000-11-15 2002-05-23 Chandavarkar Mohan A Pharmaceutival preparations comprising corticosteroids and antiinfective agents
WO2004069280A1 (en) 2003-02-06 2004-08-19 Cipla Ltd Pharmaceutical inclusion complexes containing a steroid and optionally an antibacterial agent
MXPA05008913A (es) * 2003-02-21 2005-10-05 Sun Pharmaceutical Ind Ltd Formulacion oftalmica estable que contiene antibiotico y corticoesteroide.
WO2004087100A2 (en) 2003-03-28 2004-10-14 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
PL1654002T5 (pl) 2003-08-07 2014-06-30 Allergan Inc Kompozycje do dostarczania środków terapeutycznych do oczu
CN1559413A (zh) 2004-02-26 2005-01-05 胡秀爱 地塞米松磷酸钠冻干粉针及制备方法
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
CN100584332C (zh) 2004-12-08 2010-01-27 胡世兴 含有粉防己碱的眼用制剂及其在制备治疗眼科疾病的含有粉防己碱的眼用制剂中的应用
US20080145430A1 (en) 2004-12-08 2008-06-19 Santipharp Panmai Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20080119448A1 (en) 2006-11-02 2008-05-22 Friedlaender Mitchell H Methods of treating an ocular allergy with low dose dexamethasone
ES2493641T3 (es) 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8524267B2 (en) 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
CN101926760A (zh) 2009-06-24 2010-12-29 天津金耀集团有限公司 2-羟丙基-β-环糊精包合地塞米松注射液
EP2659911A4 (en) 2010-12-28 2015-01-14 Rohto Pharma AQUEOUS OPHTHALMIC COMPOSITION
US20140163080A1 (en) * 2011-02-03 2014-06-12 Gnt, Llc Compositions and Methods for Treatment of Glaucoma
PL2662094T3 (pl) * 2012-05-08 2024-08-05 Onyx Therapeutics, Inc. Sposoby kompleksowania cylodekstryny do formułowania peptydowych inhibitorów proteasomu
KR101475776B1 (ko) 2012-08-24 2014-12-24 영진약품공업 주식회사 이중 포화 인지질을 포함하는 안정한 피부 외용 조성물
EP4218729A1 (en) * 2012-08-24 2023-08-02 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
WO2015038327A1 (en) 2013-09-10 2015-03-19 Insys Pharma, Inc. Sublingual buprenorphine spray
MA50637A (fr) 2015-05-29 2020-08-05 Oculis Ehf Formation de nanoparticules de cyclosporine a/cyclodextrine
CN107847432A (zh) 2015-05-29 2018-03-27 西德奈克西斯公司 D2o稳定化的药物制剂
TW201720445A (zh) 2015-11-13 2017-06-16 Ｏｈｒ製藥公司 角鯊胺之眼用調配物
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. POLYTHERAPY OF DISORDERS AND INFLAMMATORY EYE DISEASES
CN117018220A (zh) * 2016-11-29 2023-11-10 奥库里斯经营管理有限责任公司 用于眼用活性药物成分递送的固体环糊精复合物的制备
US11000530B2 (en) 2017-09-01 2021-05-11 Murray And Poole Enterprises Ltd Methods and compositions for the treatment of ophthalmic conditions
US20190105264A1 (en) 2017-10-06 2019-04-11 Aciont Inc. Non-invasive ocular drug delivery devices
CA3089108A1 (en) 2018-01-31 2019-08-08 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
AU2019417161B2 (en) 2018-12-27 2023-06-15 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US12097209B2 (en) * 2019-07-01 2024-09-24 Oculis Operations Sàrl Diabetic retinopathy treatment with stabilized dexamethasone
EA202290086A1 (ru) * 2020-05-12 2022-03-18 Окюлис Са СПОСОБ СТАБИЛИЗАЦИИ рН ВОДНОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ ЛЕКАРСТВЕННОЕ СРЕДСТВО
WO2023148231A1 (en) * 2022-02-02 2023-08-10 Oculis SA Multidose ophthalmic compositions
CN115837027A (zh) 2022-11-15 2023-03-24 中国药科大学 一种眼用地塞米松药物组合物

Also Published As

Publication number Publication date
TW201818943A (zh) 2018-06-01
CL2019001447A1 (es) 2019-08-09
US20240091377A1 (en) 2024-03-21
AR110270A1 (es) 2019-03-13
IL266964B1 (en) 2024-02-01
UA124774C2 (uk) 2021-11-17
LT3548091T (lt) 2022-02-10
TWI810167B (zh) 2023-08-01
ZA201903307B (en) 2020-09-30
CA3045226A1 (en) 2018-06-07
US20230042785A1 (en) 2023-02-09
TW201825100A (zh) 2018-07-16
US20190343846A1 (en) 2019-11-14
JP2022172291A (ja) 2022-11-15
US20180147297A1 (en) 2018-05-31
SMT202200025T1 (it) 2022-05-12
PT3548091T (pt) 2022-01-21
EP3548091A1 (en) 2019-10-09
MX2019006221A (es) 2019-10-07
MD3548091T2 (ro) 2022-03-31
US11135311B2 (en) 2021-10-05
MA46997B1 (fr) 2022-01-31
DK3548091T3 (da) 2022-01-17
IL310360A (en) 2024-03-01
WO2018100434A1 (en) 2018-06-07
TWI773706B (zh) 2022-08-11
JP7455917B2 (ja) 2024-03-26
EP4194011A1 (en) 2023-06-14
AU2017369971A1 (en) 2019-06-13
MA46997A (fr) 2019-10-09
BR112019011067A2 (pt) 2019-12-17
AR110269A1 (es) 2019-03-13
JP7138103B2 (ja) 2022-09-15
KR102774277B1 (ko) 2025-03-04
AU2017369971B2 (en) 2023-06-01
PH12019550088A1 (en) 2020-06-15
KR102525438B1 (ko) 2023-04-26
EA201991299A1 (ru) 2019-11-29
US20220008555A1 (en) 2022-01-13
US12233133B2 (en) 2025-02-25
IL266964B2 (en) 2024-06-01
CN117018220A (zh) 2023-11-10
KR20230025939A (ko) 2023-02-23
SI3548091T1 (sl) 2022-04-29
HUE057221T2 (hu) 2022-04-28
CY1124917T1 (el) 2023-01-05
EP3548091B1 (en) 2021-12-01
US20230037486A1 (en) 2023-02-09
KR20240036731A (ko) 2024-03-20
CN110177576B (zh) 2023-08-11
ES2903383T3 (es) 2022-04-01
KR20190091308A (ko) 2019-08-05
IL266964A (en) 2019-07-31
RS62845B1 (sr) 2022-02-28
PL3548091T3 (pl) 2022-03-28
US20250177561A1 (en) 2025-06-05
JP2019535798A (ja) 2019-12-12
MX389363B (es) 2025-03-20
US11491240B2 (en) 2022-11-08
CN110177576A (zh) 2019-08-27
HRP20220046T1 (hr) 2022-04-15

Similar Documents

Publication Publication Date Title
CO2019005729A2 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos
CL2017002636A1 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
MX2018003096A (es) Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
DOP2016000253A (es) Nuevos compuestos
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
CL2017003437A1 (es) Formulación solida oral que contiene irinotecán y método de preparación de la misma
MX2017000764A (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
RS54131B1 (en) NEW PHARMACEUTICAL FORMULATION FOR FUNGAL INFECTION TREATMENT
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
MX2017009482A (es) Formulación farmacéutica.
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
AR108368A1 (es) Preparación y dispersión de formulaciones de emulsión estable
MX2020004675A (es) Formulaciones de alcohol de seda.
AR106559A1 (es) Suspensión acuosa para administración oral y método para su preparación
BR112018013014A2 (pt) composições de higiene pessoal
CR20160432A (es) Inhibidores de las vías de señalización de wnt
MX2019000717A (es) Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos.
CL2018002200A1 (es) Administración combinada de un agente de penetración y un compuesto de azufre que contiene compuesto para las plantas.
BR112014026879A2 (pt) formulação oral, e, substrato
BR112016023737A2 (pt) ?composição agrícola, e, método de condicionamento de água?
UY37426A (es) Método para producir una composición farmacéuticamente estable presentada como una solución acuosa
AR093922A1 (es) Composicion farmaceutica que contiene telmisartan